NZ589019A - 3, 4 - substituted piperidine derivatives as renin inhibitors - Google Patents
3, 4 - substituted piperidine derivatives as renin inhibitorsInfo
- Publication number
- NZ589019A NZ589019A NZ589019A NZ58901909A NZ589019A NZ 589019 A NZ589019 A NZ 589019A NZ 589019 A NZ589019 A NZ 589019A NZ 58901909 A NZ58901909 A NZ 58901909A NZ 589019 A NZ589019 A NZ 589019A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- dihydro
- oxo
- piperidinecarboxamide
- trans
- Prior art date
Links
- -1 4 - substituted piperidine Chemical class 0.000 title 1
- 239000002461 renin inhibitor Substances 0.000 title 1
- 229940086526 renin-inhibitors Drugs 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- VZYZOSOOYGJGFD-DTWKUNHWSA-N (3S,4R)-4-(2-oxo-1H-pyridin-4-yl)piperidine-3-carboxamide Chemical class O=C1NC=CC(=C1)[C@H]1[C@@H](CNCC1)C(=O)N VZYZOSOOYGJGFD-DTWKUNHWSA-N 0.000 abstract 1
- VIPPTPJBGMBUIT-RRPNLBNLSA-N (3s,4r)-n-[[2-chloro-3,5-bis(3-methoxypropyl)phenyl]methyl]-n-cyclopropyl-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound COCCCC1=CC(CCCOC)=C(Cl)C(CN(C2CC2)C(=O)[C@H]2[C@@H](CCNC2)C2=CC(=O)N(C)C=C2)=C1 VIPPTPJBGMBUIT-RRPNLBNLSA-N 0.000 abstract 1
- HELJPBHTIIYJPZ-BJKOFHAPSA-N (3s,4r)-n-[[3-bromo-5-(3-methoxypropyl)-4-methylphenyl]methyl]-n-cyclopropyl-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound BrC1=C(C)C(CCCOC)=CC(CN(C2CC2)C(=O)[C@H]2[C@@H](CCNC2)C2=CC(=O)N(C)C=C2)=C1 HELJPBHTIIYJPZ-BJKOFHAPSA-N 0.000 abstract 1
- MNUOLBVTKBUGHT-XZOQPEGZSA-N (3s,4r)-n-[[3-bromo-5-[3-(difluoromethoxy)propyl]-4-methylphenyl]methyl]-n-cyclopropyl-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound C1=C(CCCOC(F)F)C(C)=C(Br)C=C1CN(C(=O)[C@H]1[C@@H](CCNC1)C1=CC(=O)N(C)C=C1)C1CC1 MNUOLBVTKBUGHT-XZOQPEGZSA-N 0.000 abstract 1
- AMGBGCLXZDYDOH-FCHUYYIVSA-N (3s,4r)-n-cyclopropyl-n-[[2,3-dichloro-5-(3-methoxypropyl)phenyl]methyl]-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound COCCCC1=CC(Cl)=C(Cl)C(CN(C2CC2)C(=O)[C@H]2[C@@H](CCNC2)C2=CC(=O)N(C)C=C2)=C1 AMGBGCLXZDYDOH-FCHUYYIVSA-N 0.000 abstract 1
- LPGZXVGWFKRUJB-IZZNHLLZSA-N (3s,4r)-n-cyclopropyl-n-[[5-(3-methoxypropyl)-2,3-dimethylphenyl]methyl]-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound COCCCC1=CC(C)=C(C)C(CN(C2CC2)C(=O)[C@H]2[C@@H](CCNC2)C2=CC(=O)N(C)C=C2)=C1 LPGZXVGWFKRUJB-IZZNHLLZSA-N 0.000 abstract 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010038419 Renal colic Diseases 0.000 abstract 1
- 206010063897 Renal ischaemia Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- 238000007675 cardiac surgery Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 230000036454 renin-angiotensin system Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 238000007631 vascular surgery Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12652908P | 2008-05-05 | 2008-05-05 | |
| US18830308P | 2008-08-07 | 2008-08-07 | |
| PCT/CA2009/000611 WO2009135299A1 (en) | 2008-05-05 | 2009-05-04 | 3, 4 - substituted piperidine derivatives as renin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ589019A true NZ589019A (en) | 2012-10-26 |
Family
ID=41264366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ589019A NZ589019A (en) | 2008-05-05 | 2009-05-04 | 3, 4 - substituted piperidine derivatives as renin inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8889714B2 (enExample) |
| EP (1) | EP2274295B1 (enExample) |
| JP (3) | JP4790871B2 (enExample) |
| KR (2) | KR101403311B1 (enExample) |
| CN (1) | CN102015682B (enExample) |
| AU (1) | AU2009243875B2 (enExample) |
| BR (1) | BRPI0912388A2 (enExample) |
| CA (1) | CA2722734C (enExample) |
| CO (1) | CO6311081A2 (enExample) |
| CR (1) | CR11809A (enExample) |
| DO (1) | DOP2010000329A (enExample) |
| EA (1) | EA020853B1 (enExample) |
| ES (1) | ES2548134T3 (enExample) |
| IL (1) | IL208467A (enExample) |
| MA (1) | MA32296B1 (enExample) |
| MX (1) | MX2010012067A (enExample) |
| MY (1) | MY152042A (enExample) |
| NI (1) | NI201000188A (enExample) |
| NZ (1) | NZ589019A (enExample) |
| PL (1) | PL2274295T3 (enExample) |
| SG (1) | SG192543A1 (enExample) |
| SV (1) | SV2010003723A (enExample) |
| WO (1) | WO2009135299A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| AU2009326797B2 (en) * | 2008-12-10 | 2012-12-13 | Merck Canada Inc. | 3,4 - substituted piperidine derivatives as renin inhibitors |
| TWI562977B (en) * | 2010-11-05 | 2016-12-21 | Bayer Ip Gmbh | Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| CN107602381B (zh) * | 2017-09-11 | 2021-03-16 | 陕西莱特光电材料股份有限公司 | 一种萘甲酸酯类衍生物及其制备方法 |
| CN108033876A (zh) * | 2017-12-20 | 2018-05-15 | 江汉大学 | 一种5-溴-2-氯苯甲醛的制备方法 |
| WO2020109039A1 (en) | 2018-11-28 | 2020-06-04 | Basf Se | Pesticidal compounds |
| EP4143167B1 (en) | 2020-04-28 | 2024-05-15 | Basf Se | Pesticidal compounds |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| PL193686B1 (pl) | 1995-09-07 | 2007-03-30 | Hoffmann La Roche | Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych |
| US5994294A (en) | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| CA2270118A1 (en) | 1996-11-01 | 1998-05-14 | Nitromed Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292426B1 (it) | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| KR100783863B1 (ko) | 2002-04-29 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 7-아릴-3,9-디아자바이사이클로(3.3.1)논-6-엔 유도체 및고혈압, 심혈관 질환 또는 신장 질환의 치료에서 레닌저해물질로써 이들의 용도 |
| MXPA04012136A (es) | 2002-06-27 | 2005-04-19 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tetrahidropiridina como inhibidores de renina. |
| US20040204455A1 (en) | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
| US20060217371A1 (en) | 2003-04-28 | 2006-09-28 | Olivier Bezencon | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors |
| MXPA05011478A (es) | 2003-04-29 | 2005-12-12 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,6-tetrahidropiridina 3,4-disustituidos novedosos. |
| CA2521938A1 (en) | 2003-04-30 | 2004-11-11 | Actelion Pharmaceuticals Ltd | 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors |
| MXPA05011497A (es) | 2003-04-30 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace). |
| MXPA05011496A (es) | 2003-04-30 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Derivados de azabiciclononeno. |
| EP1622564A2 (en) | 2003-05-02 | 2006-02-08 | Actelion Pharmaceuticals Ltd. | Diazabicyclononene derivatives |
| TW200513461A (en) | 2003-10-01 | 2005-04-16 | Speedel Experimenta Ag | Organische verbindungen |
| CN1863773A (zh) | 2003-10-09 | 2006-11-15 | 埃科特莱茵药品有限公司 | 四氢吡啶衍生物 |
| JP2007508262A (ja) | 2003-10-13 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規ジアザビシクロノネン誘導体およびその使用 |
| CA2540817A1 (en) | 2003-10-23 | 2005-05-06 | Olivier Bezencon | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
| US20070111989A1 (en) | 2003-12-05 | 2007-05-17 | Olivier Bezencon | Novel diazabicyclononene derivatives and use |
| US20070135406A1 (en) | 2003-12-05 | 2007-06-14 | Olivier Bezencon | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain |
| TW200613274A (en) * | 2004-07-09 | 2006-05-01 | Speedel Experimenta Ag | Organic compounds |
| CA2577084A1 (en) | 2004-08-25 | 2006-03-02 | Olivier Bezencon | Bicyclononene derivatives as renin inhibitors |
| WO2006021399A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Azabicyclononene derivatives as renin inhibitors |
| WO2006021403A1 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicyclononene derivatives |
| WO2006021401A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicylononene derivatives |
| WO2006058546A1 (en) | 2004-12-01 | 2006-06-08 | Actelion Pharmaceuticals Ltd | Novel lactame derivatives as renin inhibitors |
| TW200634014A (en) | 2004-12-08 | 2006-10-01 | Actelion Pharmaceuticals Ltd | Novel diazabicyclononene derivative |
| WO2006063610A1 (en) | 2004-12-17 | 2006-06-22 | Actelion Pharmaceuticals Ltd | Heteroaryl substituted diazabicyclononene derivatives |
| GB0428526D0 (en) * | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| CA2595986A1 (en) | 2005-01-28 | 2006-08-03 | Actelion Pharmaceuticals Ltd | 7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension |
| WO2006092268A1 (en) | 2005-03-02 | 2006-09-08 | Actelion Pharmaceuticals Ltd | Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors |
| GB0504850D0 (en) * | 2005-03-09 | 2005-04-13 | Novartis Ag | Organic compounds |
| WO2006103275A1 (en) | 2005-03-31 | 2006-10-05 | Speedel Experimenta Ag | 3,4,5-substituted piperidines as renin inhibitors |
| TW200833687A (en) | 2005-03-31 | 2008-08-16 | Speedel Experimenta Ag | Substituted piperidines |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2006253805A1 (en) * | 2005-05-27 | 2006-12-07 | Actelion Pharmaceuticals Ltd. | Novel piperidine carboxylic acid amide derivatives |
| GB0511063D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| WO2006131884A2 (en) | 2005-06-07 | 2006-12-14 | Actelion Pharmaceuticals Ltd | Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors |
| CA2615048A1 (en) | 2005-07-22 | 2007-01-25 | Merck Frosst Canada Ltd. | Renin inhibitors |
| WO2007034406A1 (en) | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
| WO2007034445A2 (en) | 2005-09-26 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency |
| WO2007049224A1 (en) | 2005-10-25 | 2007-05-03 | Actelion Pharmaceuticals Ltd | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives |
| JP5306821B2 (ja) | 2005-12-30 | 2013-10-02 | ノバルティス アーゲー | レニン阻害剤としての３，５−置換ピペリジン化合物 |
| EP1816122A3 (en) | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
| RU2425032C2 (ru) | 2006-02-02 | 2011-07-27 | Актелион Фармасьютикалз Лтд | Вторичные амины в качестве ингибиторов ренина |
| CA2642424A1 (en) | 2006-03-03 | 2007-09-07 | Actelion Pharmaceuticals Ltd. | Primary amines as renin inhibitors |
| NZ571595A (en) | 2006-03-08 | 2010-06-25 | Actelion Pharmaceuticals Ltd | New amines |
| JP2010503682A (ja) | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ， インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
| DE602007007664D1 (de) * | 2006-11-17 | 2010-08-19 | Merck Frosst Canada Inc | Renininhibitoren |
| AU2008253519A1 (en) * | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd | Novel case of renin inhibitors |
| JP2010535716A (ja) | 2007-08-07 | 2010-11-25 | メルク フロスト カナダ リミテツド | レニン阻害剤 |
| WO2009070869A1 (en) * | 2007-12-04 | 2009-06-11 | Merck Frosst Canada Ltd. | Renin inhibitors |
| AU2009250299A1 (en) | 2008-05-22 | 2009-11-26 | Merck Frosst Canada Ltd | 3, 4 - substituted piperidine derivatives as renin inhibitors |
| US20120190701A1 (en) | 2009-08-18 | 2012-07-26 | Merck Sharp & Dohme Corp. | Renin inhibitors |
-
2009
- 2009-05-04 US US12/990,927 patent/US8889714B2/en not_active Expired - Fee Related
- 2009-05-04 EP EP09741617.6A patent/EP2274295B1/en active Active
- 2009-05-04 PL PL09741617T patent/PL2274295T3/pl unknown
- 2009-05-04 CA CA2722734A patent/CA2722734C/en not_active Expired - Fee Related
- 2009-05-04 KR KR1020107024856A patent/KR101403311B1/ko not_active Expired - Fee Related
- 2009-05-04 JP JP2011507765A patent/JP4790871B2/ja not_active Expired - Fee Related
- 2009-05-04 BR BRPI0912388A patent/BRPI0912388A2/pt not_active Application Discontinuation
- 2009-05-04 KR KR1020137003332A patent/KR20130029116A/ko not_active Withdrawn
- 2009-05-04 ES ES09741617.6T patent/ES2548134T3/es active Active
- 2009-05-04 MX MX2010012067A patent/MX2010012067A/es active IP Right Grant
- 2009-05-04 AU AU2009243875A patent/AU2009243875B2/en not_active Ceased
- 2009-05-04 EA EA201071269A patent/EA020853B1/ru not_active IP Right Cessation
- 2009-05-04 SG SG2013055702A patent/SG192543A1/en unknown
- 2009-05-04 CN CN200980116219.5A patent/CN102015682B/zh not_active Expired - Fee Related
- 2009-05-04 NZ NZ589019A patent/NZ589019A/xx not_active IP Right Cessation
- 2009-05-04 MY MYPI20105036 patent/MY152042A/en unknown
- 2009-05-04 WO PCT/CA2009/000611 patent/WO2009135299A1/en not_active Ceased
-
2010
- 2010-10-04 IL IL208467A patent/IL208467A/en not_active IP Right Cessation
- 2010-11-03 DO DO2010000329A patent/DOP2010000329A/es unknown
- 2010-11-04 SV SV2010003723A patent/SV2010003723A/es not_active Application Discontinuation
- 2010-11-05 NI NI201000188A patent/NI201000188A/es unknown
- 2010-11-11 CO CO10141827A patent/CO6311081A2/es not_active Application Discontinuation
- 2010-11-11 MA MA33335A patent/MA32296B1/fr unknown
- 2010-11-24 CR CR11809A patent/CR11809A/es not_active Application Discontinuation
-
2011
- 2011-06-01 JP JP2011123057A patent/JP5653842B2/ja not_active Expired - Fee Related
- 2011-06-01 JP JP2011123054A patent/JP5587246B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010790A (es) | Derivados de heteroarilo biciclico fusionados. | |
| JP2019006834A (ja) | 毒性アルデヒド関連疾患および処置 | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| BG63487B1 (bg) | Използване на хетероциклени съединения | |
| BRPI0814065B1 (pt) | Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase | |
| CA2674548A1 (en) | Novel n-(2-aminophenyl) benzamide derivative having urea structure | |
| NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
| JP2009537590A (ja) | 四員複素環で置換された置換プテリジン | |
| EA025199B1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| JP2014502268A5 (enExample) | ||
| EP3344618A1 (de) | Substituierte oxopyridin-derivate | |
| JP7512380B2 (ja) | イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物 | |
| CA2680517A1 (en) | Novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having urea structure | |
| NO20073271L (no) | Nye pyridotienopyrimidinderivater | |
| JPWO2011148956A1 (ja) | 縮合イミダゾール誘導体 | |
| JP7086608B2 (ja) | 電位依存性ｔ型カルシウムチャネル阻害剤 | |
| JPWO2006137465A1 (ja) | 含窒素複素環誘導体 | |
| JP4950170B2 (ja) | 新規フェニルアセテート誘導体またはその薬学的に許容可能な塩、その製造方法及びそれを有効成分として含むｔ−型カルシウムイオンチャンネルの活性によって誘発される疾患の予防または治療用組成物 | |
| CA3215075A1 (en) | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | |
| MX2009010727A (es) | Heterociclos como antagonistas de orexina. | |
| NZ600748A (en) | Seven-membered ring compound and pharmaceutical use therefor | |
| WO2008053863A1 (en) | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton | |
| WO2010004221A3 (fr) | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson | |
| WO2019178324A1 (en) | Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds | |
| CN1323297A (zh) | 哒嗪酮衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 MAY 2016 BY AJ PARK Effective date: 20130517 |
|
| ASS | Change of ownership |
Owner name: ACTELION PHARMACEUTICALS LTD, CH Effective date: 20130822 |
|
| LAPS | Patent lapsed |